Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAMP4 Therapeutics
Biotech
Upstream swells IPO to $255M as it lists alongside CAMP4
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 this morning in becoming the latest biotechs to list on the Nasdaq.
James Waldron
Oct 11, 2024 5:18am
CAMP4 is latest to eye IPO, while Upstream spells out $182M plan
Oct 7, 2024 8:44am
BioMarin goes CAMPing, striking RNA deal with biotech
Oct 1, 2024 9:55am
Equipped with $100M in new cash, CAMP4 takes trail to the clinic
Jul 20, 2022 6:00am
Romanelli returns to Merck after brief CEO role—Chutes & Ladders
Apr 22, 2022 9:30am
Camp4 taps former Translate CMO for same role—Chutes & Ladders
Mar 18, 2022 9:30am
